
Topic
Clinical Evidence
Trial design, endpoints, real-world evidence, safety updates, and how evidence translates into market access.

Manufacturing· July 20, 2026 · 20 min read

Pipeline· July 17, 2026 · 17 min read
Cell & Gene Therapy Trials by the Numbers: The 2026 Registry Landscape
By Ran Chen#Gene Therapy#CAR-T#Clinical Evidence

Evidence· July 14, 2026 · 17 min read
H1 Antihistamines in FAERS: 925,032 Adverse-Event Reports

Evidence· July 12, 2026 · 17 min read
Non-HIV Antivirals in FAERS: 508,024 Adverse-Event Reports by the Numbers

Evidence· July 8, 2026 · 23 min read
Diuretic Adverse Events in FAERS: 763,000 Reports Across Three Sub-Classes

Evidence· July 8, 2026 · 28 min read
NSAID Adverse Events in FAERS: 1.5 Million Reports and the Non-Aspirin Signal Profile

Evidence· July 7, 2026 · 21 min read
Calcium Channel Blocker Adverse Events in FAERS: 619,000 Reports and Class-Wide Signals

Pricing & Access· July 5, 2026 · 16 min read
Rezdiffra (resmetirom) access: MASH drug coverage and UK MHRA authorization

Pricing & Access· July 5, 2026 · 17 min read
Winrevair (sotatercept) access landscape: PAH cost and coverage after ZENITH

Pipeline· July 2, 2026 · 17 min read
The Anti-Obesity Phase 3 Pipeline: Active Trials and Mechanisms
By Ran Chen#GLP-1#Weight Loss#Clinical Evidence